Log in
NASDAQ:ALRN

Aileron Therapeutics Stock Forecast, Price & News

$1.26
+0.03 (+2.44 %)
(As of 09/24/2020 12:00 AM ET)
Add
Compare
Today's Range
$1.15
Now: $1.26
$1.29
50-Day Range
$1.15
MA: $1.27
$1.53
52-Week Range
$0.25
Now: $1.26
$1.99
Volume246,462 shs
Average Volume692,222 shs
Market Capitalization$49.47 million
P/E RatioN/A
Dividend YieldN/A
Beta3.65
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Watertown, Massachusetts.
Read More
Aileron Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.35 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALRN
CUSIPN/A
Phone617-995-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.58 per share

Profitability

Net Income$-29,370,000.00

Miscellaneous

Employees23
Market Cap$49.47 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$1.26
+0.03 (+2.44 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ALRN News and Ratings via Email

Sign-up to receive the latest news and ratings for ALRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aileron Therapeutics (NASDAQ:ALRN) Frequently Asked Questions

How has Aileron Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aileron Therapeutics' stock was trading at $0.4031 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ALRN shares have increased by 212.6% and is now trading at $1.26.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Aileron Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aileron Therapeutics
.

When is Aileron Therapeutics' next earnings date?

Aileron Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Aileron Therapeutics
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics Inc (NASDAQ:ALRN) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.05.
View Aileron Therapeutics' earnings history
.

What price target have analysts set for ALRN?

3 analysts have issued 1 year price objectives for Aileron Therapeutics' stock. Their forecasts range from $2.00 to $5.00. On average, they anticipate Aileron Therapeutics' stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 177.8% from the stock's current price.
View analysts' price targets for Aileron Therapeutics
.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 802,100 shares, an increase of 10.9% from the August 15th total of 723,300 shares. Based on an average daily volume of 901,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 3.1% of the shares of the stock are short sold.
View Aileron Therapeutics' Short Interest
.

Who are some of Aileron Therapeutics' key competitors?

What other stocks do shareholders of Aileron Therapeutics own?

Who are Aileron Therapeutics' key executives?

Aileron Therapeutics' management team includes the following people:
  • Dr. Manuel C. Aivado, Pres, CEO & Director (Age 49)
  • Mr. Donald V. Dougherty C.F.A., C.P.A., CPA, CFA, Sr. VP & CFO (Age 60)
  • Mr. Richard J. Wanstall, VP of Fin. & Operations
  • Dr. D. Allen Annis Ph.D., Sr. VP of Research (Age 46)
  • Dr. Vojislav Vukovic M.D., Ph.D., Sr. VP & Chief Medical Officer (Age 52)

When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Blair William & Co. IL (0.61%), Personal CFO Solutions LLC (0.12%), Goldman Sachs Group Inc. (0.06%) and Virtu Financial LLC (0.06%). Company insiders that own Aileron Therapeutics stock include Bioventures Ltd Novartis, Jeffrey Allen Bailey, Kathryn Gregory, Reinhard J Ambros, Rickenbach Josef H Von and Vojo Vukovic.
View institutional ownership trends for Aileron Therapeutics
.

Which major investors are selling Aileron Therapeutics stock?

ALRN stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL.
View insider buying and selling activity for Aileron Therapeutics
.

Which major investors are buying Aileron Therapeutics stock?

ALRN stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Personal CFO Solutions LLC, and Virtu Financial LLC. Company insiders that have bought Aileron Therapeutics stock in the last two years include Jeffrey Allen Bailey, Kathryn Gregory, Reinhard J Ambros, Rickenbach Josef H Von, and Vojo Vukovic.
View insider buying and selling activity for Aileron Therapeutics
.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $1.26.

How big of a company is Aileron Therapeutics?

Aileron Therapeutics has a market capitalization of $49.47 million. The company earns $-29,370,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Aileron Therapeutics employs 23 workers across the globe.

What is Aileron Therapeutics' official website?

The official website for Aileron Therapeutics is www.aileronrx.com.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-995-0900 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.